Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03362554

Identification of New Biomarkers of Insulin Resistance

Diabetes is a chronic metabolic disease affecting 415 million people worldwide, 90% of cases are type 2 which is frequently associated with obesity and a sedentary lifestyle. In healthy individuals, insulin stimulates increased cell surface expression of a glucose transporter (GLUT4) in muscle and fat tissue. This prevents blood sugar levels becoming dangerously high by taking sugar into the muscle and fat cells. Loss of this response ('insulin resistance') frequently occurs before the development of type 2 diabetes. Understanding the cell biology of insulin resistance is necessary to develop more effective treatments for this condition and prevent further cases of type 2 diabetes. Previous work showed that this movement of GLUT4 is dependent on a small protein called Rab3 which is downregulated in insulin resistance. Rab3 protein levels are also sensitive to inflammation, a state that is exacerbated by obesity.

In order to examine whether Rab3 is an early biomarker of insulin resistance, we aim to measure the levels of this protein and its interactors in fat and muscle samples from insulin resistant individuals. It has been shown that insulin sensitivity can be improved with an intervention as short as three weeks when net energy intake is sufficiently reduced. Therefore, by taking the same measurements before and after this three week intervention we can observe any improvements in Rab3 expression and insulin sensitivity at a cellular level.

There is also evidence for an effect of the gut microbiome on insulin sensitivity so we will measure any changes that take place in the gut microbiome following this intervention, which can be determined from faecal samples taken before and after the three weeks.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

40 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department for Health, University of Bath

Bath, BA2 7AY, United Kingdom

About this study

Diabetes is a chronic metabolic disease affecting 415 million people worldwide and 3.5 million people in the UK, with ninety percent suffering from type 2 diabetes. Type 2 diabetes is characterised by the inability of muscle and fat tissues to adequately respond to physiological levels of insulin (peripheral tissue insulin resistance), and to restore the normal levels of sugars in the bloodstream. Insulin resistance may occur prior to the development of type 2 diabetes and has been shown to be strongly linked to lifestyle and to obesity, although the underlying mechanisms are incompletely resolved. A defining characteristic of insulin resistance is abnormal glucose transport as a result of decreased cell surface expression of the glucose receptor GLUT4. In healthy adipose and skeletal muscle this receptor is trafficked to the cell surface in response to an insulin stimulus. We have shown that this translocation to the cell membrane requires the protein Rab3, and expression levels of this protein are reduced in cell models of insulin resistance.

We hypothesise that this downregulation of Rab3 is associated with the development of insulin resistance and its activity would increase following the restoration of insulin sensitivity. The primary aim of this study is to examine the effect on Rab3 levels and GLUT4 trafficking of a diet and exercise intervention that has been previously shown to increase insulin sensitivity. Additionally, the gut microbiome will be studied before and after the intervention to determine any relationship to insulin sensitivity. Recent evidence suggests the microbiome has a significant role in the development of insulin resistance through a number of potential mechanisms. Infusion of microbiota from lean donors has been shown to result in improved insulin sensitivity in male recipients with metabolic syndrome, with concomitant increases in the prevalence of butyrate-producing intestinal microbiota. Exercise is associated with greater microbial diversity, including increases in butyrate-producing microbes. No study to date has monitored insulin sensitivity and microbiota composition before and after an exercise and diet intervention, and so this will lead to a better understanding of the mechanisms that lead to insulin resistance and subsequently type 2 diabetes.

The study participants will include males and females aged between 40-65 years who fit the criteria for inclusion. After monitoring of normal daily activities for 7 days, volunteers will reduce their calorie intake by 5000 kcal/week and take part in 5 weekly exercise sessions for 3 weeks. Participants will attend one session of laboratory testing before and one after this period which will take place at the University of Bath. This intervention should be sufficient to improve insulin sensitivity and allow us to study the cellular changes that will have taken place during this time.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • Age 40-65
  • BMI ≥25 to ≤ 40 kg/m2
  • Physical activity level <1.75 (daily average)
  • Waist size >80 cm (female) or >94 cm (male)
  • Weight stable for >3 months

Exclusion criteria

  • Inability to undertake exercise as determined by PAR-Q
  • Diagnosed diabetes
  • Ongoing or planned lifestyle changes (diet/exercise)
  • Recent large shift in bodyweight (>2.5%) within the last 3 months?
  • Smoker (or having ceased <6mo ago)
  • Metabolic disorders
  • Hypertension defined as >160/100
  • Use of anti-inflammatory medication: NSAIDs
  • Cardiovascular disease
  • Any bleeding disorder or taking anticoagulant medication
  • Use of antibiotics within the last three months
  • Use of pro/pre-biotics within one month of first trial day.

Treatment and study plan

Controlled diet and exercise.

Behavioral

The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:

  • Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.
  • Reduction of their standard diet by 5000 kcal per week

Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken.

Primary outcomes

  1. Change in insulin sensitivity

    Time frame: 120 min (change after 3 weeks)

    Response to oral glucose tolerance test

Secondary outcomes

  1. Rab3 protein expression

    Time frame: Change after 3 weeks

    Levels of Rab3 in adipose and muscle samples

  2. GLUT4 pathway protein expression

    Time frame: Change after 3 weeks

    Expression levels of GLUT4 pathway proteins in adipose and muscle samples

  3. Metabolic markers

    Time frame: Change after 3 weeks

    Levels of circulating metabolic markers implicated in insulin resistance

  4. Inflammatory markers

    Time frame: Change after 3 weeks

    Levels of circulating inflammatory cytokines

  5. Gut microbiome

    Time frame: Change after 3 weeks

    Species of microorganisms present in fecal samples

  6. Body composition

    Time frame: Change after 3 weeks

    Assessed by whole body DEXA scan

  7. Waist circumference

    Time frame: Change after 3 weeks

  8. Body mass

    Time frame: Change after 3 weeks

Sponsors and collaborators

Lead sponsor

University of Bath

Other

Collaborators

  • Teagasc

Registry information

Important dates

Study start
2018
Primary completion
2024
Study completion
2028
First posted
Dec 5, 2017
Registry last updated
Nov 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.